Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and angiotensin-converting enzyme activity in humans

Current Hypertension Reports

Volumn 3, Issue SUPPL. 2, 2001, Pages

  Vesterqvist, Ole ^a   Reeves, Richard A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATRIAL NATRIURETIC FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; OMAPATRILAT; PYRIDINE DERIVATIVE; THIAZEPINE DERIVATIVE; VASODILATOR AGENT;

ANIMAL; BLOOD PRESSURE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; HUMANS; HYPERTENSION; NEPRILYSIN; PYRIDINES; RENIN-ANGIOTENSIN SYSTEM; THIAZEPINES; VASODILATOR AGENTS;

EID: 1642270417     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-001-0103-x     Document Type: Article

References (42)

1. Burnett JC: Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens 1999, 17(Suppl 1):S37-S43.
2. Asher JR, Naftilan AJ: Vasopeptidase inhibition: a new direction in cardiovascular treatment. Curr Hypertens Rep 2000, 2:384-391.
3. Erdös EG, Skidgel RA: Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989, 3:145-151.
4. Roques BP, Noble F, Daugé V, et al.: Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 1993, 45:87-146. (Pubitemid 23108243)
5. Chappell MC, Allred AJ, Ferrario CM: Pathways of angiotensin- (1-7) metabolism in the kidney. Nephrol Dial Transplant 2001, 16(Suppl):122-126.
6. Bevan EG, Connell JMC, Doyle J, et al.: Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992, 10:607-613.
7. Richards AM, Crozier IG, Kosoglou T, et al.: Endopeptidase 24.11 inhibition by SCH 42495 in essential hypertension. Hypertension 1993, 22:119-126. (Pubitemid 23187393)
8. Stergiou GS, Hannah JA, Bevan EG, et al.: Combined atriopeptidase inhibition and angiotensin converting enzyme inhibition in hypertensive patients. J Hypertens 1994, 12:1310-1311.
9. Robl JA, Sun C-Q, Stevenson J, et al.: Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem 1997, 40:1570-1577. (Pubitemid 27231460)
10. Trippodo NC, Robl JA, Asaad MM, et al.: Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998, 11:363-372. (Pubitemid 28186749)
11. Intengan HD, Schiffrin EL: Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats. Hypertension 2000, 35:1221-1225. (Pubitemid 30413654)
12. Quaschning T, d'Uscio LV, Shaw S, et al.: Vasopeptidase inhibition exhibits endothelial protection in salt-sensitive hypertension. Hypertension 2001, 37:1108-1113. (Pubitemid 32304012)
13. Trippodo NC, Fox M, Monticello TM, et al.: Simultaneous inhibition of neutral endopeptidase and angiotensin covering enzyme by omapatrilat increased survival in heart failure hamsters greater than ACE inhibition [abstract]. Circulation 1998, 98:I-781.
14. Vesterqvist O, Manning JA, Uderman H, et al.: Effects of BMS- 186716, a new dual metalloprotease inhibitor, on pharmacodynamic markers of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE) activity in healthy men [abstract]. Clin Pharmacol Ther 1997, 61:230. (Pubitemid 127791618)
15. Vesterqvist O, Liao W, Manning JA, et al.: Pharmacodynamic effects of multiple doses of omapatrilat in healthy subjects [abstract]. Clin Pharmacol Ther 1999, 65:132.
16. Ferrario CM, Smith RD, Yunis C, et al.: Angiotensin-(1-7) and vasopeptidase inhibition [abstract]. Am J Hypertens 2000, 13:23A.
17. Flickinger AL, Burnett JC, Turner ST: Atrial natriuretic peptide and blood pressure in a population-based sample. Mayo Clin Proc 1995, 70:932-938.
18. Deutch A, Frishman WH, Sukenik D, et al.: Atrial natriuretic peptide and its potential role in pharmacotherapy. J Clin Pharmacol 1994, 34:1133-1147.
19. Northridge DB, Newby DE, Rooney E, et al.: Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. Am Heart J 1999, 138:1149-1157.
20. Yandle TG, Richards AM, Nicholls MG, et al.: Metabolic clearance rate and plasma half life of alpha-human atrial natriuretic peptide in man. Life Sci 1986, 38:1827-1833. (Pubitemid 16068742)
21. Epstein M, Loutzenhiser R, Friedland E, et al.: Relationship of increased plasma atrial natriuretic factor and renal sodium handling during immersion-induced central hypervolemia in normal humans. J Clin Invest 1987, 79:738-745. (Pubitemid 17050897)
22. Solomon LR, Atherton JC, Bobinski H, et al.: Effect of posture on plasma immunoreactive atrial natriuretic peptide concentrations in man. Clin Sci 1986, 71:299-305. (Pubitemid 16058740)
23. Campese VM, Ferrario CM, Ruddy MC, et al.: Omapatrilat or lisinopril in salt-sensitive hypertensives [abstract]. Am J Hypertens 2000, 13:A15.
24. McClean DR, Ikram H, Garlick AH, et al.: The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patient with chronic heart failure. J Am Coll Cardiol 2000, 36:479-486. (Pubitemid 30624011)
25. Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med 1998, 339:321-328. (Pubitemid 28366422)
26. Richards AM, Wittert G, Espiner EA, et al.: Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circ Res 1992, 71:1501-1507.
27. Motwani JG, Lang CC, Cramb G, et al.: Natriuretic responses to neutral endopeptidase inhibition is blunted by enalapril in healthy men. Hypertension 1995, 25:637-642.
28. Massien C, Azizi M, Guyene TT, et al.: Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans. Clin Pharmacol Ther 1999, 65:448-459. (Pubitemid 29196549)
29. Kitamura K, Kangawa K, Kawamoto M, et al.: Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993, 192:553-560. (Pubitemid 23227359)
30. Jougasaki M, Wei C, Aarhus L, et al.: Renal localization and actions of adrenomedullin: a natriuretic peptide. Am J Physiol 1995, 268:F657-F663.
31. Lainchbury J, Cooper G, Coy D, et al.: Adrenomedullin: a hypotensive hormone in man. Clin Sci 1997, 92:467-472. (Pubitemid 27214205)
32. Jougasaki M, Wei C, McKinley L, et al.: Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 1995, 92:286-289.
33. Lisy O, Jougasaki M, Schirger J, et al.: Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. Am J Physiol 1998, 275:F410-F414.
34. Vesterqvist O, Campese VM, Liao W, et al.: Omapatrilat increases plasma concentrations of adrenomedullin in salt-sensitive hypertensives [abstract]. Am J Hypertens 2000, 13:125A.
35. Ferrario CM: Angiotensin-(1-7) and antihypertensive mechanisms. J Nephrol 1998, 11:278-283. (Pubitemid 29071216)
36. Liao W, Delaney CL, Manning JA, et al.: Marked elevation in plasma renin activity [PRA] in response to omapatrilat in healthy, normotensive males [abstract]. Circulation 1998, 98:3802.
37. Ruddy M, Guthrie R, Papademetriou V: The safety and 24-hour antihypertensive efficacy of the vasopeptidase inhibitor omapatrilat: a pilot study [abstract]. Am J Hypertens 1999, 12:125A.
38. Zusman R, Atlas S, Kochar M, et al.: Efficacy and safety of omapatrilat, a vasopeptidase inhibitor [abstract]. Am J Hypertens 1999, 12:125A.
39. Weber M: Emerging treatments for hypertension: Potential role for vasopeptidase inhibition. Am J Hypertens 1999, 12:139S-147S.
40. Liao W, Delaney CL, Beierle FA, et al.: Omapatrilat, a novel vasopeptidase inhibitor, reduces blood pressure in normotensive subjects [abstract]. J Am Coll Cardiol 1999, 33:309A.
41. Rouleau JL: The neurohumoral hypothesis and the treatment of heart failure. Can J Cardiol 1996, 12(Suppl F):3-8.
42. Rouleau JL, Pfeffer MA, Stewart DJ, et al.: Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000, 356:615-620. (Pubitemid 30627587)